Dimensional Fund Advisors LP Buys 171,933 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Dimensional Fund Advisors LP grew its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,067,951 shares of the biopharmaceutical company's stock after acquiring an additional 171,933 shares during the period. Dimensional Fund Advisors LP owned about 3.09% of Dynavax Technologies worth $51,948,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DVAX. E Fund Management Co. Ltd. lifted its position in shares of Dynavax Technologies by 4.6% during the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock worth $225,000 after purchasing an additional 771 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Dynavax Technologies by 7.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 904 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares during the last quarter. Sanctuary Advisors LLC grew its stake in shares of Dynavax Technologies by 6.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock valued at $245,000 after acquiring an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on DVAX. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday. HC Wainwright reiterated a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group dropped their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. Finally, JMP Securities lowered their price objective on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Dynavax Technologies presently has a consensus rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Trading Down 1.3 %

DVAX stock traded down $0.13 during mid-day trading on Thursday, reaching $9.59. 630,834 shares of the stock traded hands, compared to its average volume of 2,218,596. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 52-week low of $9.29 and a 52-week high of $14.63. The stock's fifty day moving average is $12.41 and its 200-day moving average is $12.57. The company has a market cap of $1.17 billion, a P/E ratio of 53.28 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. As a group, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.